From Trial Data to Clinical Practice: DVRd, MRD Testing, and Payer Coverage Considerations in NDMM

This episode, titled 'From Trial Data to Clinical Practice: DVRd, MRD Testing, and Payer Coverage Considerations in NDMM,' features multiple myeloma experts discussing the following critical questions:

1. DVRd showed meaningful PFS and MRD negativity benefits in both CGS-defined high-risk and standard-risk patients. Given that the benefit extended across risk groups, does this data reinforce your confidence in DVRd as a universal frontline standard?
2. Do these results raise more questions of whether we need risk-adapted intensification beyond DVRd for the highest-risk patients?
3. With DVRd now supported by both traditional FISH-based and NGS-based risk analyses in PERSEUS, do you see this data influencing payer coverage or formulary decisions, particularly for high-risk patients?

Led by the moderator, the panelists examined the clinical significance of DVRd's demonstrated PFS and MRD negativity benefits across both high-risk and standard-risk patient populations, reinforcing confidence in its role as a broadly applicable frontline standard while acknowledging that MRD negativity is not an all-or-none outcome, with some patients achieving durable long-term remissions even without reaching MRD-negative status, underscoring the importance of nuanced patient communication that contextualizes MRD results without creating unnecessary anxiety. The discussion also explored whether the DVRd data raises questions about the need for risk-adapted intensification beyond the current standard, with the panelists agreeing that while the data supports a broad quadruplet approach, the field urgently needs prospective trial evidence to guide MRD-based treatment de-escalation and re-intensification decisions. The panelists further addressed the potential implications of NGS-based risk analysis for payer coverage and formulary decisions, expressing caution about the risk of payers implementing restriction policies before clinical practice has fully established risk-adapted treatment algorithms.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'CEPHEUS at 6 Years: Counseling Transplant-Ineligible Patients and Managing DVRd in Frail Populations,' panelists will continue their discussion on multiple myeloma and highlight what the CEPHEUS six-year durability data means for how clinicians counsel transplant-ineligible patients about their long-term prognosis, and how dose modifications and supportive care strategies are being applied to ensure frail and older patients can safely benefit from DVRd.